Monro Extends Poison Pill to November 2027 Amid Strategic-Alternatives Review
MNRO is trading near its 52-week low of $11.06 (9.5% above the low).
Summary
Monro extended its rights plan's expiration from November 6, 2026 to November 1, 2027, saying the extra year supports its ongoing review of strategic alternatives. No other terms of the plan changed.
Key Events · Corporate Governance and Compliance · MNRO
-
Rights Plan Extended One Year
The final expiration date moves from 5:00 p.m. Eastern on November 6, 2026 to 5:00 p.m. Eastern on November 1, 2027, unless the rights are earlier redeemed, exchanged or terminated.
-
Tied to Strategic-Alternatives Review
The board said the extension is meant to preserve its ability to conduct the review effectively and protect shareholder interests during it, implying the review remains open.
-
Plan Economics Unchanged
Exercise price stays at $90.00 per one one-thousandth of a share of Series D Junior Participating Serial Preferred Stock, and the company retains the right to redeem rights at $0.01 per right.
-
Amendment Effective Immediately
Executed November 4, 2026 with Equiniti Trust Company, LLC as rights agent; it becomes effective on execution without holder approval under Section 27 of the agreement.
Analysis · MNRO · Trade & Services
Monro pushed the expiration of its shareholder rights plan out a full year, from November 6, 2026 to November 1, 2027, explicitly to keep the board's leverage intact while it reviews strategic alternatives. A poison pill does not change earnings or cash flow, but its extension tells shareholders the strategic review is still live and unresolved, and that the board wants a defense in place against hostile or unsolicited approaches while it runs. The $90.00 per one-thousandth-of-a-share preferred purchase price and $0.01 per right redemption terms are unchanged, so this is a duration change, not a new economic instrument. The practical read: no deal has been signed, and the board is buying itself time.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MNRO was trading at $12.11 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $379.4M. The 52-week trading range was $11.06 to $23.91. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.